Loading, please wait...
CONTINUING PHARMACY EDUCATION
Specialty, Oncology, and ID Drugs: What Is in the Pipline?
The 2025 Update
Speaker: Liya Davydov, PharmD, BCPS, BCGP, Senior Director, Clinical Pharmacy Services, Continuum of Care, Premier Inc, Charlotte, NC
ACPE Universal Program ID# 0122-0000-26-021-H01-P/T
1 Contact Hours [0.1 CEU]
Release Date: March 2, 2026
Expiration Date: March 2, 2029
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists and Pharmacy Technicians
Accreditation(s)
|
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
Specialty, Oncology and ID Drugs: What Is in the Pipeline? The 2025 Update
Specialty, Oncology and ID Drugs: What Is in the Pipeline? The 2025 Update
There are 2 steps to completing this home-study CE.
Step 1: Watch the video presentation in its entirety.
Step 2: Click on "Take the Test" to complete the post-test and evaluation.
Please Note: A handout is provided. Please print it out and follow along with the audio recording.
Objectives
- Describe growth trends of specialty/oncology agents in the pharmaceutical pipeline
- Identify notable agents that have been recently approved, are in the late stages of development, or are under regulatory review for infectious diseases indications
- Identify specialty drugs that are currently under regulatory review for select indications
- List oral oncology agents that are currently under regulatory review for various cancers
- Recognize parenteral oncology agents that are currently under regulatory review for various cancers
Speaker(s)/Author(s)
|
Liya Davydov, PharmD, BCPS, BCGP
|
Activity Number
0122-0000-26-021-H01-P/T
Release Date:
Mar 2, 2026
Credit Expiration Date:
Mar 2, 2029
CE Hours
1.00